November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
17 citations
,
June 2020 in “British Journal of Dermatology” Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
November 2022 in “Journal of Investigative Dermatology” Statins may help treat alopecia areata by reducing harmful immune interactions.
98 citations
,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
January 2026 in “Journal of Sexual and Mental Health” New male contraceptive pills show promise in reducing sperm production with mild side effects.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
July 2024 in “Reactions Weekly”
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
2 citations
,
April 2019 in “Journal of the American Society of Nephrology” Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
11 citations
,
March 2024 in “Current Issues in Molecular Biology” Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.
February 2026 in “Indian Dermatology Online Journal” Tofacitinib significantly improved skin and hair conditions without side effects.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.